Evidence map›Paper›PMID 30527239›Full record

ArticleOral oncology2018

UM-HACC-2A: MYB-NFIB fusion-positive human adenoid cystic carcinoma cell line.

Kristy A Warner, Alexandra E Oklejas, Alexander T Pearson, Zhaocheng Zhang, Weishing Wu, Vasu Divi, Christie Rodriguez-Ramirez, Rogerio M Castilho, Peter J Polverini, Jacques E Nör

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oral oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Emerging role of MYB transcription factors in cancer drug resistance.Cancer drug resistance (Alhambra, Calif.) · 2024
    Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Systemic therapies for salivary gland adenoid cystic carcinoma.American journal of cancer research · 2021
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Kristy A WarnerDepartment of Cariology, Restorative Sciences, Endodontics, University of Michigan School of Dentistry, Ann Arbor, MI 48109, USA.
Alexandra E OklejasDepartment of Cariology, Restorative Sciences, Endodontics, University of Michigan School of Dentistry, Ann Arbor, MI 48109, USA.
Alexander T PearsonDept of Medicine, University of Chicago, USA.
Zhaocheng ZhangDepartment of Cariology, Restorative Sciences, Endodontics, University of Michigan School of Dentistry, Ann Arbor, MI 48109, USA.
Weishing WuBiomedical Research Core Facility, University of Michigan, Ann Arbor, MI, USA.
Vasu DiviDepartment of Otolaryngology, Stanford University, Stanford, CA, USA.
Christie Rodriguez-RamirezDepartment of Cariology, Restorative Sciences, Endodontics, University of Michigan School of Dentistry, Ann Arbor, MI 48109, USA.
Rogerio M CastilhoDepartment of Periodontics and Oral Medicine, School of Dentistry, Ann Arbor, MI 48109, USA.
Peter J PolveriniDepartment of Periodontics and Oral Medicine, School of Dentistry, Ann Arbor, MI 48109, USA.
Jacques E NörDepartment of Cariology, Restorative Sciences, Endodontics, University of Michigan School of Dentistry, Ann Arbor, MI 48109, USA; Department of Biomedical Engineering, University of Michigan College of Engineering, Ann Arbor, MI, USA; Department of Otolaryngology, University of Michigan School of Medicine, Ann Arbor, MI, USA; Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, USA. Electronic address: jenor@umich.edu.
University of Michigan · USStanford University · USUniversity of Chicago · US

Funding

Salivary gland cancer stem cellsR01DE021139 · NIDCR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Jacques Eduardo Nor · 2011 to 2026
$5.8M
Therapeutic Inhibition of MDM2/Bcl-2 in Pre-clinical Models of Adenoid Cystic CarR01DE023220 · NIDCR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI NOR, JACQUES EDUARDO · 2012 to 2015
$1.5M
A reasoned approach to combination therapy development in head and neck cancerK08DE026500 · NIDCR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PEARSON, ALEXANDER THOMAS · 2016 to 2020
$800k
NIDCR NIH HHS K08 DE026500NIDCR NIH HHS R01 DE021139NIDCR NIH HHS R01 DE023220
6 · The paper itself

Abstract

objectivesLimited availability of validated human adenoid cystic carcinoma (ACC) cell lines has hindered the mechanistic understanding of the pathobiology of this malignancy and the development of effective therapies. The purpose of this work was to generate and characterize a human ACC cell line. MATERIAL AND

methodsImmediately after surgery, a tumor fragment from a minor salivary gland from the tongue of a female Caucasian was minced, dissociated, and a single cell suspension was plated in fibronectin-coated flasks. A culture medium containing bovine brain extract and rhEGF was optimized for these cells. Whole exome sequencing was used to evaluate the presence of MYB-NFIB translocation.

resultsThe University of Michigan-Human Adenoid Cystic Carcinoma (UM-HACC)-2A cells showed continuous growth in monolayers for at least 180 in vitro passages while maintaining epithelial morphology. Short-tandem repeat (STR) profiling confirmed a 100% match to patient DNA. Whole exome sequencing revealed the presence of the MYB-NFIB fusion in UM-HACC-2A cells, which was confirmed by PCR analysis. Western blots revealed high expression of epithelial markers (e.g. E-cadherin, EGFR, pan-cytokeratin) and proteins associated with ACC (e.g. c-Myb, p63). Developmental therapeutic studies showed that UM-HACC-2A cells were resistant to cisplatin (IC

conclusionUM-HACC-2A is a MYB-NFIB fusion-positive ACC cell line that is suitable for mechanistic and developmental therapeutics studies.

Indexed as

AnimalsCarcinoma, Adenoid CysticCell Line, TumorFemaleHumansMiceMice, SCIDMiddle AgedOncogene Proteins, FusionPaclitaxelPrimary Cell CultureSalivary Gland NeoplasmsSalivary GlandsXenograft Model Antitumor AssaysMYB-NFIB fusion protein, humanOncogene Proteins, FusionPaclitaxelC-MybExperimental modelsExperimental therapeuticsGene fusionMYB-NFIBOncogeneOrthotopicSalivary glandSalivary gland cancer

Identifiers

PMID30527239
PMCPMC6294471
OpenAlexW2896419620

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.